Cargando…

A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota

BACKGROUND: Successful chemoprevention or chemotherapy is achieved through targeted delivery of prophylactic agents during initial phases of carcinogenesis or therapeutic agents to malignant tumors. Bacteria can be used as anticancer agents, but efforts to utilize attenuated pathogenic bacteria suff...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Yusook, Ryu, Yongku, An, Byung Chull, Yoon, Yeo-Sang, Choi, Oksik, Kim, Tai Yeub, Yoon, Jaekyung, Ahn, Jun Young, Park, Ho Jin, Kwon, Soon-Kyeong, Kim, Jihyun F., Chung, Myung Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157686/
https://www.ncbi.nlm.nih.gov/pubmed/34039418
http://dx.doi.org/10.1186/s40168-021-01071-4
_version_ 1783699737432555520
author Chung, Yusook
Ryu, Yongku
An, Byung Chull
Yoon, Yeo-Sang
Choi, Oksik
Kim, Tai Yeub
Yoon, Jaekyung
Ahn, Jun Young
Park, Ho Jin
Kwon, Soon-Kyeong
Kim, Jihyun F.
Chung, Myung Jun
author_facet Chung, Yusook
Ryu, Yongku
An, Byung Chull
Yoon, Yeo-Sang
Choi, Oksik
Kim, Tai Yeub
Yoon, Jaekyung
Ahn, Jun Young
Park, Ho Jin
Kwon, Soon-Kyeong
Kim, Jihyun F.
Chung, Myung Jun
author_sort Chung, Yusook
collection PubMed
description BACKGROUND: Successful chemoprevention or chemotherapy is achieved through targeted delivery of prophylactic agents during initial phases of carcinogenesis or therapeutic agents to malignant tumors. Bacteria can be used as anticancer agents, but efforts to utilize attenuated pathogenic bacteria suffer from the risk of toxicity or infection. Lactic acid bacteria are safe to eat and often confer health benefits, making them ideal candidates for live vehicles engineered to deliver anticancer drugs. RESULTS: In this study, we developed an effective bacterial drug delivery system for colorectal cancer (CRC) therapy using the lactic acid bacterium Pediococcus pentosaceus. It is equipped with dual gene cassettes driven by a strong inducible promoter that encode the therapeutic protein P8 fused to a secretion signal peptide and a complementation system. In an inducible CRC cell-derived xenograft mouse model, our synthetic probiotic significantly reduced tumor volume and inhibited tumor growth relative to the control. Mice with colitis-associated CRC induced by azoxymethane and dextran sodium sulfate exhibited polyp regression and recovered taxonomic diversity when the engineered bacterium was orally administered. Further, the synthetic probiotic modulated gut microbiota and alleviated the chemically induced dysbiosis. Correlation analysis demonstrated that specific bacterial taxa potentially associated with eubiosis or dysbiosis, such as Akkermansia or Turicibacter, have positive or negative relationships with other microbial members. CONCLUSIONS: Taken together, our work illustrates that an effective and stable synthetic probiotic composed of P. pentosaceus and the P8 therapeutic protein can reduce CRC and contribute to rebiosis, and the validity and feasibility of cell-based designer biopharmaceuticals for both treating CRC and ameliorating impaired microbiota. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01071-4.
format Online
Article
Text
id pubmed-8157686
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81576862021-05-28 A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota Chung, Yusook Ryu, Yongku An, Byung Chull Yoon, Yeo-Sang Choi, Oksik Kim, Tai Yeub Yoon, Jaekyung Ahn, Jun Young Park, Ho Jin Kwon, Soon-Kyeong Kim, Jihyun F. Chung, Myung Jun Microbiome Research BACKGROUND: Successful chemoprevention or chemotherapy is achieved through targeted delivery of prophylactic agents during initial phases of carcinogenesis or therapeutic agents to malignant tumors. Bacteria can be used as anticancer agents, but efforts to utilize attenuated pathogenic bacteria suffer from the risk of toxicity or infection. Lactic acid bacteria are safe to eat and often confer health benefits, making them ideal candidates for live vehicles engineered to deliver anticancer drugs. RESULTS: In this study, we developed an effective bacterial drug delivery system for colorectal cancer (CRC) therapy using the lactic acid bacterium Pediococcus pentosaceus. It is equipped with dual gene cassettes driven by a strong inducible promoter that encode the therapeutic protein P8 fused to a secretion signal peptide and a complementation system. In an inducible CRC cell-derived xenograft mouse model, our synthetic probiotic significantly reduced tumor volume and inhibited tumor growth relative to the control. Mice with colitis-associated CRC induced by azoxymethane and dextran sodium sulfate exhibited polyp regression and recovered taxonomic diversity when the engineered bacterium was orally administered. Further, the synthetic probiotic modulated gut microbiota and alleviated the chemically induced dysbiosis. Correlation analysis demonstrated that specific bacterial taxa potentially associated with eubiosis or dysbiosis, such as Akkermansia or Turicibacter, have positive or negative relationships with other microbial members. CONCLUSIONS: Taken together, our work illustrates that an effective and stable synthetic probiotic composed of P. pentosaceus and the P8 therapeutic protein can reduce CRC and contribute to rebiosis, and the validity and feasibility of cell-based designer biopharmaceuticals for both treating CRC and ameliorating impaired microbiota. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-021-01071-4. BioMed Central 2021-05-26 /pmc/articles/PMC8157686/ /pubmed/34039418 http://dx.doi.org/10.1186/s40168-021-01071-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chung, Yusook
Ryu, Yongku
An, Byung Chull
Yoon, Yeo-Sang
Choi, Oksik
Kim, Tai Yeub
Yoon, Jaekyung
Ahn, Jun Young
Park, Ho Jin
Kwon, Soon-Kyeong
Kim, Jihyun F.
Chung, Myung Jun
A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
title A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
title_full A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
title_fullStr A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
title_full_unstemmed A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
title_short A synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
title_sort synthetic probiotic engineered for colorectal cancer therapy modulates gut microbiota
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157686/
https://www.ncbi.nlm.nih.gov/pubmed/34039418
http://dx.doi.org/10.1186/s40168-021-01071-4
work_keys_str_mv AT chungyusook asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT ryuyongku asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT anbyungchull asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT yoonyeosang asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT choioksik asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT kimtaiyeub asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT yoonjaekyung asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT ahnjunyoung asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT parkhojin asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT kwonsoonkyeong asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT kimjihyunf asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT chungmyungjun asyntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT chungyusook syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT ryuyongku syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT anbyungchull syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT yoonyeosang syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT choioksik syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT kimtaiyeub syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT yoonjaekyung syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT ahnjunyoung syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT parkhojin syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT kwonsoonkyeong syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT kimjihyunf syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota
AT chungmyungjun syntheticprobioticengineeredforcolorectalcancertherapymodulatesgutmicrobiota